Tenax Therapeutics
TENX
21 hedge funds and large institutions have $4.25M invested in Tenax Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
25,168% more capital inflows, than outflows
Capital inflows: $4.4M | Capital outflows: $17.4K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
91% more funds holding
Funds holding: 11 → 21 (+10)
35.08% more ownership
Funds ownership: 0.96% → 36.04% (+35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$1.23M |
| 2 |
Vivo Capital
Palo Alto,
California
|
+$755K |
| 3 |
VR Adviser
New York
|
+$755K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$302K |
| 5 |
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$302K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$13.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.94K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$1.09K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3 |
TENX Hedge Fund Activity: Q3 2024 in Review
21 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q3 2024, worth a combined $4.25M — up 7,334% from $57.2K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TENX positions and 4 closed out — a net gain of 10 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $1.23M. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $13.4K sold.
- 21 institutional investors held Tenax Therapeutics (TENX) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $4.25M of Tenax Therapeutics stock for Q3 2024, up 7,334% quarter-over-quarter.
- 14 funds opened new Tenax Therapeutics positions in Q3 2024 and 4 closed out, a net change of +10 holders.
- The largest Tenax Therapeutics buyer in Q3 2024 was BVF Inc, an estimated $1.23M added.
- The largest Tenax Therapeutics seller in Q3 2024 was Qube Research & Technologies (QRT), an estimated $13.4K sold.
Based on aggregated 13F filings for Q3 2024.